RxDoctor Payments Data

Christopher Connelly, MD

Clinical Neurophysiology · Concord, NCNPI 1457321978

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $308 and has fallen 81.7% since, to $56 in 2025.

$431in general payments, 2019–2025

Across 22 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$72
  • Amgen$56
  • AbbVie$47
  • Bristol Myers Squibb$43
  • TG Therapeutics, Inc.$38
  • Pfizer$34
  • plus $141 from 7 others

What the payments were for

  • Food & beverage$431100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few clinical neurophysiology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$99,569
Medicare patients
475
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$211,380
VumerityDiroximel Fumarate21$174,566
IngrezzaValbenazine Tosylate19$162,150
Aimovig AutoinjectorErenumab-Aooe135$115,363
UbrelvyUbrogepant43$67,122
NuplazidPimavanserin Tartrate13$64,383
QuliptaAtogepant53$62,043
Nurtec OdtRimegepant Sulfate25$51,946
Emgality SyringeGalcanezumab-Gnlm40$37,794
SavellaMilnacipran Hcl51$33,200
EliquisApixaban19$15,691
Emgality PenGalcanezumab-Gnlm19$13,261
MyrbetriqMirabegron16$12,967
Ajovy AutoinjectorFremanezumab-Vfrm17$12,578
Gabapentin546$10,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$16$211,38014 claims
BiogenVumerity$72$174,56621 claims
AbbVieUbrelvy, Qulipta, Savella, Linzess$47$169,300160 claims
PfizerNurtec Odt, Eliquis$34$67,63744 claims
Lilly USA, LLCCymbalta$32$6,77512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →